Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic Colorectal Cancer

Area of Science:

• Oncology
• Genomics
• Precision Medicine

Background:

• Metastatic colorectal cancer (mCRC) exhibits diverse genomic alterations beyond established markers.
• Emerging targets like ERBB2 amplifications, mutations, and fusions offer new therapeutic avenues.
• Understanding the genomic landscape in specific populations is crucial for personalized treatment.

Purpose of the Study:

• To comprehensively analyze the genomic profile of a Chinese mCRC cohort.
• To identify prevalent and potentially targetable genetic alterations.
• To correlate molecular findings with overall survival (OS) for prognostic insights.

Main Methods:

• Targeted next-generation sequencing (NGS) of 520 genes on tumor tissues from 500 mCRC patients.
• Analysis of mutations, microsatellite instability (MSI), and mismatch repair deficiency.
• Estimation of overall survival (OS) in relation to identified molecular alterations.

Main Results:

• High frequencies of TP53 (78%), APC (60%), and KRAS (47%) mutations were observed.
• ERBB2/HER2 amplifications occurred in 12% of patients, with therapeutic potential.
• BRAF V600E mutations (12.2%) were linked to poorer prognosis, while KRAS mutations did not significantly impact OS.

Conclusions:

• NGS is effective for detecting prognostic and actionable variants in Chinese mCRC patients.
• This study enhances understanding of genomic variations in this population.
• Findings support the potential of personalized medicine for mCRC management.